ClinicalTrials.gov
public full text
Public Domain
Durvalumab and Tremelimumab in Resectable HCC
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC#326310
- TheraSphere With Durvalumab and Tremelimumab for HCC#407726
- Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC#860170
- Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial#326315
- Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10)#813765
Record · ID 474758
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive